ライフサイエンスコーパス: kidney transplantation

1 imilar with TacHexal and Prograf early after kidney transplantation.

2 on may be appropriate for all patients after kidney transplantation.

3 ct on HO-1 upregulation after deceased donor kidney transplantation.

4 cies that attempt to maximize survival after kidney transplantation.

5 d has a high propensity for recurrence after kidney transplantation.

6 s well as competition in improving access to kidney transplantation.

7 ising preconditioning strategies before ABOi kidney transplantation.

8 r reason for late allograft loss in clinical kidney transplantation.

9 of patients with AA nephropathy (AAN) after kidney transplantation.

10 usal chain surrounding racial disparities in kidney transplantation.

11 etter understanding of racial disparities in kidney transplantation.

12 esent a surgical challenge in the context of kidney transplantation.

13 - and 3-year mortality among dialysis versus kidney transplantation.

14 ss of kidney function requiring dialysis and kidney transplantation.

15 on with market competition in the conduct of kidney transplantation.

16 ney perfusion (NEVKP) in heart-beating donor kidney transplantation.

17 osis remains an important complication after kidney transplantation.

18 tized patients an opportunity for successful kidney transplantation.

19 rsistent hyperparathyroidism is common after kidney transplantation.

20 ograft may help realize the full benefits of kidney transplantation.

21 ith the compounding issues of CKD, ESRD, and kidney transplantation.

22 that decrease long-term graft survival after kidney transplantation.

23 ir suppressive function predictive of AKI in kidney transplantation.

24 lead to the recurrence of proteinuria after kidney transplantation.

25 be a potential intervention also in clinical kidney transplantation.

26 rt-term patient and allograft survival after kidney transplantation.

27 s were followed up from 1 to 36 months after kidney transplantation.

28 hange estimated racial/ethnic disparities in kidney transplantation.

29 uency of secondary hyperparathyroidism after kidney transplantation.

30 with an increased acute rejection rate after kidney transplantation.

31 herapeutic targets for improving outcomes of kidney transplantation.

32 arding the effect of stopping smoking before kidney transplantation.

33 ay to predict the long-term outcome of human kidney transplantation.

34 disease with a high rate of recurrence after kidney transplantation.

35 evel greater than 200 mumol/L at day 7 after kidney transplantation.

36 most concerned with the financial burden of kidney transplantation.

37 tched nondonors who underwent deceased donor kidney transplantation.

38 ffect social participation in patients after kidney transplantation.

39 sease about all treatment options, including kidney transplantation.

40 (n = 2) underwent full MHC-mismatched heart/kidney transplantation.

41 sfunction influences candidate selection for kidney transplantation.

42 in pathway on long-term graft survival after kidney transplantation.

43 o list for and receipt of simultaneous liver kidney transplantation.

44 s used as a criterion for simultaneous liver-kidney transplantation.

45 end-stage renal disease and recurrence after kidney transplantation.

46 oadsorption column reuse in ABO-incompatible kidney transplantation.

47 oes not improve delayed graft function after kidney transplantation.

48 ications of prescription narcotic use before kidney transplantation.

49 aking decisions regarding simultaneous liver-kidney transplantation.

50 Proteinuria occurs commonly after kidney transplantation.

51 med, with 4 of the 27 including simultaneous kidney transplantation.

52 se patients with ESRD have limited access to kidney transplantation.

53 8-year-old boy with previous living-related kidney transplantation.

54 total of 27 HIV-positive patients underwent kidney transplantation.

55 , no relevant literature exists on CRS after kidney transplantation.

56 ation, especially in patients considered for kidney transplantation.

57 patients on dialysis on the waiting list for kidney transplantation.

58 ir influence on the practice of living donor kidney transplantation.

59 o influence graft survival in deceased-donor kidney transplantation.

60 ter I/R injury of mice and in patients after kidney transplantation.

61 hrologists' attitudes to patients' access to kidney transplantation.

62 anocytic squamous cell carcinoma (SCC) after kidney transplantation.

63 verity of infections in the first year after kidney transplantation.

64 l gastrectomy was evaluated for living donor kidney transplantation.

65 hort of 538 patients in the first year after kidney transplantation.

66 kidney transplantation who received a second kidney transplantation.

67 adverse cardiovascular outcomes in pediatric kidney transplantation.

68 ing these core outcome domains for trials in kidney transplantation.

69 atients were excluded from consideration for kidney transplantation.

70 iated with increased risk of mortality after kidney transplantation.

71 tation of core outcome domains for trials in kidney transplantation.

72 nt cause of loss of allograft function after kidney transplantation.

73 ed protein 4 Ig) is an emerging treatment in kidney transplantation.

74 ies against mismatched donor HLA antigens in kidney transplantation.

75 clinical trials of Treg therapy in liver and kidney transplantation.

76 trolled NEVKP improves renal function in DCD kidney transplantation.

77 sed safely and effectively in patients after kidney transplantation.

78 e the consistency and relevance of trials in kidney transplantation.

79 ecision was to submit the patient to a liver-kidney transplantation.

80 a scenario that is common in bone marrow and kidney transplantation.

81 were three main subgroups: 18 patients after kidney transplantation, 10 patients with gastrointestina

82 tudy period, there were 385,498 listings for kidney transplantation, 252 of which were prior donors.

83 Living donor (LD) kidney transplantation accounts for around half of all p

84 ADPKD) than by lower rates of deceased donor kidney transplantation after waitlisting (rates were onl

85 does not account for the racial disparity in kidney transplantation after waitlisting.

86 val advantage for SPK recipients compared to kidney transplantation alone (KTA) is controversial.

87 ion treated with IIT and to 13 patients with kidney transplantation alone or simultaneous pancreas-ki

88 -related nephrotoxicity, and developments in kidney transplantation among HIV-positive individuals.

89 ur understanding of fracture incidence after kidney transplantation and how it compares to nontranspl

90 aimed to evaluate antibiotic prophylaxis in kidney transplantation and identify risk factors for SSI

91 predictors of myocardial recovery following kidney transplantation and long-term outcomes.

92 frequent in immunosuppressed patients after kidney transplantation and may lead to allograft failure

93 l cytotoxic CD4(+) CD28(null) cell subset in kidney transplantation and points to strategies that may

94 ng clinical trial data on acute rejection in kidney transplantation and response to Infliximab in ulc

95 antibody (dnDSA) during the first year after kidney transplantation and the impact of early dnDSA on

96 term immunosuppressive drug treatment due to kidney transplantation and the second case is a malignan

97 d on historical practice patterns related to kidney transplantation and were never designed to minimi

98 cardinal causes of late allograft loss after kidney transplantation, and there is great need for noni

99 who had CKD stage 5 at presentation received kidney transplantation; and 1 patient required further h

100 nderwent haploidentical MHC-mismatched heart/kidney transplantation; and group 4 (n = 2) underwent fu

101 on SSIs were deceased donor, thin ureters at kidney transplantation, antithymocyte globulin induction

102 recurrence rate of AAGN within 5 years after kidney transplantation appeared slightly higher than in

103 The maternofetal outcomes in patients with kidney transplantation are comparable with those of nont

104 al and economic consequences of cancer after kidney transplantation are incompletely defined.

105 urrent trends in cardiovascular events after kidney transplantation are poorly understood.

106 ection of delayed graft function (DGF) after kidney transplantation are unreliable.

107 Although clinical DCD lung, liver, and kidney transplantation are well established, transplanta

108 tive liver transplantations and living-donor kidney transplantations are also now on the horizon.

109 sease (ESRD) patients are not educated about kidney transplantation as a treatment option at the time

110 urine output at days 1, 7, 15, and 30 after kidney transplantation as well as at hospital discharge.

111 We reviewed 232 patients who underwent kidney transplantation at the Cleveland Clinic from 2003

112 fied critically important outcome domains in kidney transplantation based on the shared priorities of

113 pation in patients 3 months to 6 years after kidney transplantation (baseline) and their impact on gr

114 d for market characteristics associated with kidney transplantation between 2003 and 2012.

115 ated in 240 patients who were waitlisted for kidney transplantation between 2008 and 2010, and patien

116 Of the 1,054 patients who underwent kidney transplantation between September 2004 and Decemb

117 -inhibitor free immunosuppressive therapy in kidney transplantation but is associated with a higher a

118 Obesity represents a barrier to kidney transplantation, but the increasing prevalence am

119 with antibody-mediated rejection (AMR) after kidney transplantation by rituximab and plasmapheresis i

120 cular risk factor assessment in selection of kidney transplantation candidates for cardiac evaluation

121 In kidney transplantation candidates, CACS outperformed ris

122 issing in-hospital mortality, admission post kidney transplantation, chronic renal replacement therap

123 lantation of kidney grafts in combined liver-kidney transplantation (CLKT).

124 on of endogenous stem cells immediately post kidney transplantation combined with repeat therapy at 1

125 Although cardiac evaluation before kidney transplantation commonly focuses on coronary arte

126 ion in the Reducing Disparities in Access to kidNey Transplantation Community Study (RaDIANT), a rand

127 Despite a significant survival advantage of kidney transplantation compared with dialysis, nearly on

128 antly worse graft and patient outcomes after kidney transplantation compared with nonindigenous Austr

129 Despite improvements in kidney transplantation, complications, including cardiov

130 t maintenance immunosuppression regimens for kidney transplantation, concerns about toxicity have mad

131 an aTreg percentage higher than 1.46% before kidney transplantation conferred an increased risk of AR

132 Kidney transplantation confers a well-documented surviva

133 trategies to improve graft outcome following kidney transplantation consider information at the human

134 s) (95% confidence intervals [CI]) for first kidney transplantation, controlling for year, demographi

135 Kidney transplantation corrects or improves many complic

136 ents and increasing access to deceased donor kidney transplantation (DDKT) for highly sensitized pati

137 h worse allograft survival in deceased-donor kidney transplantation (DDKT) from AA donors.

138 Patients in the United States waiting for kidney transplantation die in increasing numbers owing t

139 Dual kidney transplantation (DKT) is an underused way to expa

140 Morbid obesity is a barrier to kidney transplantation due to inferior outcomes, includi

141 al study involving 95 children who underwent kidney transplantation due to NS, excluding congenital c

142 ents (decrease in eGFR of >30%, dialysis, or kidney transplantation) during a 3-year follow-up.

143 After kidney transplantation, early readmission is independent

144 esity among children starting RRT may impede kidney transplantation, especially from living donors.

145 Disparities in kidney transplantation evident for blacks and Hispanics

146 ining bone marrow transplantation (BMT) with kidney transplantation following non-myeloablative condi

147 tified all patients who underwent LSG before kidney transplantation from 2011-2016 (n = 20).

148 llosensitization in two recipients following kidney transplantation from a highly sensitized donor.

149 Kidney transplantation from an HIV-positive donor appear

150 Kidney transplantation from deceased donors aged 65 year

151 tudy demonstrates that despite the fact that kidney transplantation from elderly deceased donors is a

152 This is one of the first cases of kidney transplantation from the same donor after previou

153 In pediatric kidney transplantation, graft survival of kidneys from d

154 Robotic kidney transplantation group had a significantly higher

155 group 1 (n = 3) underwent class I-mismatched kidney transplantation; group 2 (n = 3) underwent 2 sequ

156 3) underwent 2 sequential class I-mismatched kidney transplantations; group 3 (n = 2) underwent haplo

157 Donation after circulatory death (DCD) kidney transplantation has acceptable renal allograft su

158 Kidney transplantation has become a routine procedure in

159 Dual kidney transplantation has been based on histological as

160 the incidence of cardiovascular events after kidney transplantation has changed from 1994 to 2009.

161 The gap between supply and demand in kidney transplantation has led to increased use of margi

162 Clinical experience in kidney transplantation has revealed a high incidence of

163 rategies to improve allograft survival after kidney transplantation have been directed to recipient-d

164 invasive pulmonary aspergillosis (IPA) after kidney transplantation have been poorly explored.

165 uppression, graft and patient outcomes after kidney transplantation have improved considerably.

166 dinal follow-up of eight children undergoing kidney transplantation, HDL-induced production of endoth

167 ality of life (HRQOL) usually improved after kidney transplantation; however, a non-negligible number

168 h an increased morbidity and mortality after kidney transplantation; however, their clinical utility

169 multaneous islet-kidney (SIK) or islet-after-kidney transplantation (IAK) are rare and have never bee

170 desensitization and incompatible live donor kidney transplantation (ILDKT) constitute a unique subpo

171 Since the first living-donor kidney transplantation in 1954, more than half a million

172 risk factors, and compare this to access to kidney transplantation in 2012.

173 inhibitor therapy after low-to-moderate risk kidney transplantation in 3 randomized trials.

174 donor evaluation and augment living related kidney transplantation in ADPKD.

175 plant BMI on the risk of graft failure after kidney transplantation in both unadjusted and adjusted m

176 ducted a prospective, nonrandomized study of kidney transplantation in HIV-infected patients who had

177 The outcome of kidney transplantation in human immunodeficiency virus (

178 To determine the survival benefit of kidney transplantation in human immunodeficiency virus (

179 y a poor indicator of the potential need for kidney transplantation in LMIC.

180 t-dependent cytotoxicity-negative crossmatch kidney transplantation in Paris (2000-2010).

181 Current data regarding the outcome of kidney transplantation in patients with familial Mediter

182 Kidney transplantation in recipients with a previous mal

183 ents who started HHD with those who received kidney transplantation in the United States between 2007

184 on for prior donors who were wait-listed for kidney transplantation in the United States.

185 pective trial including all ABO-incompatible kidney transplantations in Switzerland from 2005 to 2011

186 g of baseline serum creatinine, dialysis, or kidney transplantation) in the adjusted analyses (P<0.01

187 icentric Swiss protocol for ABO-incompatible kidney transplantation including immunoadsorption column

188 ced a national protocol for ABO-incompatible kidney transplantation including immunoadsorption column

189 assing a spectrum of renal dysfunction after kidney transplantation including those who may or may no

190 erence to immunosuppressive medication after kidney transplantation is a behavioral issue and as such

191 Early graft loss (EGL) after kidney transplantation is a catastrophic outcome that is

192 Kidney transplantation is a cost-saving treatment that e

193 ng conditions, the need for midodrine before kidney transplantation is a risk marker for complication

194 Kidney transplantation is a viable treatment for select

195 mmalian target of rapamycin inhibitors after kidney transplantation is associated with a concentratio

196 Kidney transplantation is associated with improved cardi

197 Induction therapy in deceased donor kidney transplantation is costly, with wide discrepancy

198 epigenetic modifications on the outcomes of kidney transplantation is currently poorly understood an

199 Deceased-donor kidney transplantation is frequently performed at weeken

200 The waiting list for kidney transplantation is long.

201 ABO-incompatible (ABOi) kidney transplantation is now an established form of ren

202 Cardiac evaluation before kidney transplantation is recommended, but no unequivoca

203 Kidney transplantation is the best treatment option for

204 For many patients, kidney transplantation is the preferred treatment modali

205 Kidney transplantation is the treatment of choice for ES

206 usion until transplant: 69 with simultaneous kidney transplantation (KT) (at time of LT, group 1) and

207 ts reported in the literature that underwent kidney transplantation (KT) after a previous HSCT from t

208 ompleting the work-up (WU) and/or undergoing kidney transplantation (KT) but this has not been well d

209 The old-for-old allocation policy used for kidney transplantation (KT) has confirmed the survival b

210 SUMMARY BACKGROUND DATA: Although kidney transplantation (KT) has emerged as a viable opti

211 Minimally invasive approaches to kidney transplantation (KT) have been described recently

212 thnicity was associated with lower access to kidney transplantation (KT) in a Canadian setting.

213 s are affected by significant disparities in kidney transplantation (KT) in Veterans Affairs (VA) and

214 Kidney transplantation (KT) may restore fertility in chr

215 Kidney transplantation (KT) of human immunodeficiency vi

216 ospital readmission and mortality risk among kidney transplantation (KT) recipients.

217 invasive pulmonary aspergillosis (IPA) after kidney transplantation (KT) remain poorly studied.

218 nsplant Research data, we compared access to kidney transplantation (KT), time from ESRD to listing,

219 an aggravated risk of this malignancy after kidney transplantation (KT).

220 cidence of fractures in the first year after kidney transplantation (KT).

221 Early rehospitalization after kidney transplantation (KTx) is common and is considered

222 in rates of preKT, focusing on living donor kidney transplantation (LDKT) and specifically recipient

223 he presence of sex disparity in living donor kidney transplantation (LDKT) remains controversial.

224 an important tool to facilitate living donor kidney transplantation (LDKT).

225 eceive disproportionately fewer living donor kidney transplantations (LDKTs) than non-Hispanic whites

226 Unlike chronic organ failure in kidney transplantation, lymphangiogenesis is not altered

227 We hypothesized that midodrine use before kidney transplantation may be a novel marker for posttra

228 sing patterns across periods of dialysis and kidney transplantation may inform cancer etiology.

229 Lower rates of kidney transplantation may, therefore, mediate the highe

230 ns for apparent disease-specific barriers to kidney transplantation might inform center-specific tran

231 The lack of new drug development in kidney transplantation necessitated repurposing drugs in

232 The increased use of ABOi kidney transplantation needs to be matched with randomiz

233 importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and pro

234 econditioning therapies in living donor ABOi kidney transplantation on graft and patient outcomes.

235 Bone marrow transplantation (BMTx), kidney transplantation, or a combination of both were pe

236 history of pretransplant melanoma, previous kidney transplantation, or transplantation after 2012 or

237 Differences in kidney transplantation outcomes across GN subtypes have

238 Kidney transplantation patients with estimated glomerula

239 death and survival on dialysis compared with kidney transplantation patients.

240 Data of all first kidney transplantation performed before 30 years of age

241 Among 635 consecutive kidney transplantations performed between 2008 and 2010,

242 Robotic kidney transplantation permits transplantation in extrem

243 ith adverse patient and graft outcomes after kidney transplantation, pilot data suggest that PH may i

244 The five donor nephrectomies made nine kidney transplantations possible.

245 rticosteroid withdrawal (CW) after pediatric kidney transplantation potentially improves growth while

246 igh levels of prescription opioid use before kidney transplantation predict increased risk of posttra

247 Preemptive kidney transplantation (preKT) is associated with higher

248 , blood group, renal replacement time, prior kidney transplantation, race, gender, diabetes, and tran

249 Reduced kidney transplantation rates among comparator groups wer

250 Whether kidney transplantation rates differ by glomerulonephriti

251 es for all clinical stakeholders to increase kidney transplantation rates, and reduce total costs of

252 We evaluated all kidney transplantation recipients from January 2009 and

253 Genetic analysis was performed in 464 kidney transplantation recipients to evaluate whether tr

254 own encouraging results for the treatment of kidney transplantation recipients with focal segmental g

255 of transplantation in 19 450 deceased donor kidney transplantation recipients with Medicare as prima

256 In kidney transplantation recipients with recurrent FSGS, r

257 s including our results was performed (total kidney transplantation recipients, n = 3105).

258 ongitudinal MMF doses, and graft loss in 525 kidney transplantation recipients.

259 ing as an important, novel domain of risk in kidney transplantation recipients.

260 (BMI) on long-term allograft outcomes after kidney transplantation remains controversial.

261 Treatment decisions in kidney transplantation requires patients and clinicians

262 s for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively.

263 s for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively.

264 zation in pediatric blood group incompatible kidney transplantation results in excellent outcomes wit

265 Here, we show that kidney transplantation "reverse nephrectomy" is also ass

266 t was best with the Rotterdam Comorbidity in Kidney Transplantation score compared to separate comorb

267 The Rotterdam Comorbidity in Kidney Transplantation score was developed, and its infl

268 Kidney transplantation should be promoted by expanding d

269 Population needs for kidney transplantation should instead be assessed based

270 a therapy in patients on dialysis undergoing kidney transplantation should take into account the poss

271 viously described signatures of tolerance in kidney transplantation showing the differential expressi

272 ts who reach end-stage renal disease, single kidney transplantation (SKT) or combined kidney-pancreas

273 to determine the need for simultaneous liver kidney transplantation (SLK) versus liver alone transpla

274 herapy at 3 months) after simultaneous liver-kidney transplantation (SLKT).

275 alysis, pancreas after simultaneous pancreas-kidney transplantation/solitary pancreatic transplantati

276 ysis revealed that the risk factors for post-kidney transplantation SSIs were deceased donor, thin ur

277 unosuppression therapy, deceased donor, post-kidney transplantation SSIs, and delayed graft function.

278 national Standardized Outcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops i

279 rge registry study comparing dialysis versus kidney transplantation survival outcomes of waitlisted a

280 n large registries, survival is longer after kidney transplantation than when remaining on dialysis.

281 After kidney transplantation, the percentage of TIM-3+, PD-1+,

282 0.31 to 0.93); with censoring of time after kidney transplantation, the relative hazard was 0.56 (95

283 Unlike kidney transplantation, the rs4730751 variant in our pan

284 st that Tregs may not have a central role in kidney transplantation tolerance.

285 Longitudinal cohort study in adult kidney transplantation transplanted at a single-center b

286 eceased donors) and the risk of cancer after kidney transplantation using adjusted Cox proportional h

287 dren with steroid-resistant NS who underwent kidney transplantation using next-generation sequencing.

288 ibed the outcomes of adult living donor ABOi kidney transplantations using any form of preconditionin

289 Kidney transplantation was associated with improved 5-ye

290 In each group, orthotopic kidney transplantation was performed after recipient nep

291 Primary kidney transplantation was performed on 1609 patients fr

292 Simultaneous liver kidney transplantation was recommended for patients with

293 Using a stringent mouse model of allogeneic kidney transplantation, we demonstrated that acute allog

294 Kidney transplantations were performed from dark agouti

295 ts chronic rejection changes in experimental kidney transplantation which indicates that sunitinib co

296 as do not properly reflect renal function in kidney transplantation, which makes their use in clinica

297 squamous cell carcinoma (SCC) after a first kidney transplantation who received a second kidney tran

298 Kidney transplantation with low-level DSA with or withou

299 T) and specifically recipients who underwent kidney transplantation within 1 year of initiating dialy

300 se patients and allowed them to benefit from kidney transplantation without an increased risk of oppo